JPRN-jRCTs021210013已完成4 期
Effect of dotinurad in hyperuricemia with hypertension (DIANA) - DIANA
ode Koichi0 个研究点目标入组 54 人开始时间: 2021年6月24日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 54
研究概览
简要总结
This study (the DIANA study) is a physician-initiated, multicenter, prospective, non-randomized, single-arm, open-label clinical trial to evaluate the effects of 24 weeks of dotinurad treatment on clinical measures, primarily serum uric acid levels, in hyperuricemic patients with treated hypertension. In the DIANA study, a total of 50 eligible patients were treated with dotinurad for 24 weeks and showed a significant reduction in the primary endpoint, a percent change in serum uric acid -35.8% (95% CI -39.7
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Patients aged 20 years or older at the time when consent was obtained (regardless of gender)
- •2) Patients with hyperuricemia and a serum uric acid level of greater than 7.0 mg/dL
- •3) Patients with hypertension, who meet the definition of JSH2019, without change in the pharmacological and/or non-pharmacological treatment for hypertension within 4 weeks prior to eligibility assessment
- •4) Patients who provided their written consent to participate in this research
排除标准
- •1) Patients whose inflammation did not subside after acute gouty arthritis
- •2) Patients who are currently suffering from urolithiasis
- •3) Patients with known secondary hyperuricemia who are suffering from any of the following diseases:
- •Lesch-Nyhan syndrome, phosphoribosyl pyrophosphate synthetase superactivity, congenital myogenic hyperuricemia, hematopoietic organ tumor (acute leukemia, malignant lymphoma, myeloproliferative disorder, myelodysplastic syndrome), solid tumor (breast cancer, seminoma, sarcoma, Wilms tumor, small cell lung cancer), non-neoplastic disease (psoriasis vulgaris, secondary polycythemia, hemolytic anemia), tumor lysis syndrome, rhabdomyolysis, hypothyroidism, polycystic kidney, lead poisoning/lead nephropathy, Down's syndrome, familial juvenile gouty nephropathy, hyperlactacidemia, or glycogen storage disease type I
- •4) Patients with hypertensive emergency and urgency
- •5) Patients with complications from active malignancy
- •6) Patients with serious hepatic dysfunction
- •7) Patients with severe renal dysfunction with oliguria or anuria
- •8) Patients who are pregnant, suspected to be pregnant, or breastfeeding
- •9) Patients with a history of hypersensitivity to the ingredients contained in dotinurad preparations
- •10) Patients who the principal investigator or subinvestigator considers not suitable for this study
研究者
相似试验
招募中
Unknown
Clinical Study on Dotinurad for HyperuricemiaJPRN-UMIN000054142Sekino Hospital40
招募中
4 期
Survey of dotinurad use in hyperuricemic patients with impaired renal function-A retrospective observational studyPatients with hyperuricemia (renal function as eGFR category G1-G5)JPRN-jRCT1051230149Shimazu keiji500
已完成
3 期
A Study to Evaluate Efficacy of Dotinurad and Febuxostat for the Treatment of Participants With GoutGoutNCT05007392Eisai Co., Ltd.451
已完成
2 期
A Study of RDEA806 in Hyperuricemic Subjects With Symptomatic GoutHyperuricemiaNCT00741442Ardea Biosciences, Inc.3
已完成
2 期
A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AMLAcute Myeloid LeukemiaNCT03280030Novartis Pharmaceuticals67